Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Analyze how volatile dividend aristocrats ETF behaves in retirement and what that means for your withdrawal plan. This intro helps readers gauge risk and plan smarter.
21,930 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Analysts lift Occidental targets to as high as $69, citing Permian efficiency and robust cash flow. Oil near $75 prov...
Coca-Cola and Philip Morris International both beat expectations in Q1 2026 and now sit near 52-week highs. Analysts ...
Greg Abel, seen as Warren Buffett's successor, made a bold move by trimming UnitedHealth from Berkshire's portfolio. ...
As AI drives demand for faster memory, Micron sits at the center of a cyclical industry that can fuel outsized moves....
Micron Technology posted a surprisingly strong AI memory quarter, triggering debate over whether the stock’s 7x forwa...
A sharp 178% EPS rise is grabbing attention, paired with an insider stock sale at Rogers Corp. This article breaks do...
Microsoft has faced a sharp pullback as AI spending and cloud dynamics shift. This article weighs the risks and oppor...
As TopBuild (BLD) closes 2025, investors look for how revenue, margins, and backlog shape the 2026 outlook. This arti...
Netflix just posted a record quarterly revenue, but the forecast for the next quarter came in softer than expected. H...
Goldman Sachs and KeyBanc boosted AT&T price targets after the telecom giant unveiled a three-segment reporting model...
Cracker Barrel’s 2026 earnings story hinges on traffic trends, pricing power, and margin discipline. This guide break...